Virionics’ Virus-Like Particle Technology is cornerstone of agreement.

Intas Biopharmaceuticals and Virionics are partnering for development of an HPV vaccine for cervical cancer. The development of the HPV therapeutic (HPV-16 & HPV-18) will be based on the Virionics’ Virus-Like Particle technology.

The collaboration provides for technology transfer and exclusive marketing rights to Intas for supply of the product in India and certain other key markets.

“The companies will jointly initiate a development program and create a development committee, comprising members of the two companies, which will be responsible for creating, modifying, and monitoring the program,” explains Shri Mani Iyer, director at Intas. “The committee will be responsible for providing strategic preclinical, manufacturing, and clinical study and simultaneously executing a clinical program to support the combination product. Additionally, Intas will have the first option to be a contract manufacturing supplier of the product, for India and other markets. Process development and yield improvement activities will be carried out at Intas.”

Previous articleAvexa Wins Grant for HIV Drug Discovery Program
Next articleCeNeRx Gains Access to PharmaNess’ Cannabinoid Portfolio